A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma
Clinical trial NCT03126591 · COMPLETED
Trial details
- NCT number
- NCT03126591
- Sponsor
- Eli Lilly and Company
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2017-07-03
- Primary completion
- 2021-05-06
- Enrollment
- 41
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.